(3) Tumor progression after first-line treatment with a fluoropyrimidine (5-FU, S-1, or capecitabine) combined with a platinum-based agent (oxaliplatin or cisplatin), or single-agent chemotherapy plus a PD-1/PD-L1 inhibitor. Here, CD274 is linked to neoplasm.